Healthcare Industry News: arrhythmia
News Release - March 20, 2012
Thermedical Announces Series A Financing Round
Innovative Ablation Therapy May Significantly Alter Cancer TreatmentSOMERVILLE, Mass.--(Healthcare Sales & Marketing Network)--Thermedical, a privately held company developing proprietary thermal therapy equipment for numerous clinical conditions, today announced that it closed $1.5 million in Series A funding with a private investor, Samuel H. Maslak, Sc.D. The financing will fund continued research and development, and additional patent filings; it will also help the company achieve 510(k) regulatory clearance from the U.S. Food & Drug Administration (FDA).
Thermedical is developing preclinical prototypes for a Saline-Enhanced Radio Frequency (SERF™) ablation system for treating malignant solid tissue, such as liver cancer, and for difficult-to-treat cardiac arrhythmias, such as ventricular tachycardia (VT).
“I am investing in Thermedical and joining its Board of Directors because I believe the SERF Ablation Technology will dramatically improve the efficacy of ablation therapy,” said Dr. Maslak, chairman of the board of directors at Thermedical. “I project that this revolutionary technology will alter the course of treatment for patients with liver cancer and other solid tumors, and that it will deliver a cost-effective cure for VT.
“It’s clear to me that Thermedical will become an important, highly profitable company developing and selling thermal therapies. Simply put, SERF Ablation Technology will be a game-changer in both cancer and VT treatment.”
About Thermedical
Based in Somerville, Mass., Thermedical is a privately held company founded by Michael G. Curley, Ph.D., and Patrick S. Hamilton, Ph.D. Under multiple National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Grants and a Massachusetts Life Sciences Center Small Business Matching Grant (SBMG) Award, Thermedical is developing thermal ablation systems to treat previously untreatable cancer and cardiac arrhythmias. The ablation therapy system is designed to increase survival and improve quality of life for liver cancer patients, and be a cure for VT. Additional information may be found by visiting http://www.thermedical.com.
SERF Ablation is a trademark of Thermedical.
Source: Thermedical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.